Genetic test evaluation: Information needs of clinicians, policy makers, and the public

American Journal of Epidemiology

Volumn 156, Issue 4, 2002, Pages 311-318

  Burke, Wylie ^a   Atkins, David ^b   Gwinn, Marta ^c   Guttmacher, Alan ^d   Haddow, James ^e   Lau, Joseph ^f   Palomaki, Glenn ^e   Press, Nancy ^g   Richards, C Sue ^h   Wideroff, Louise ⁱ   Wiesner, Georgia L ^j   Khoury, Muin ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^e FOUNDATION FOR BLOOD RESEARCH   (United States)

^f TUFTS MEDICAL CENTER   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j CASE WESTERN RESERVE UNIVERSITY   (United States)

more..

Author keywords

Factor V; Genetic markers; Genetic predisposition to disease; Genetic screening; Genetics; Phenylketonurias

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN;

GENETICS;

ARTICLE; DATA ANALYSIS; DISEASE ASSOCIATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; HUMAN; LEGAL ASPECT; MEDICAL ETHICS; MEDICAL INFORMATION; PHENYLKETONURIA; SOCIAL ASPECT; STANDARDIZATION; THROMBOEMBOLISM; VALIDATION PROCESS;

DECISION MAKING; EPIDEMIOLOGY; ETHICS, MEDICAL; FACTOR V; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; PHENYLKETONURIAS; REFERENCE VALUES; SOCIAL CONDITIONS; VENOUS THROMBOSIS;

EID: 0037103382     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/aje/kwf055     Document Type: Article

References (39)

1. Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations
2. Shattuck lecture - Medical and societal consequences of the Human Genome Project
3. Pharmacogenetics and the practice of medicine
4. Promoting safe and effective genetic testing in the United States. Final report of the Task Force on Genetic Testing
5. Evidence-based medicine and practice guidelines: An overview
6. Development of practice guidelines
7. Lessons learned from newborn screening for phenylketonuria
8. The history of newborn phenylketonuria screening in the United States
9. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC
10. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2
11. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening
12. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis
13. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen
14. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation
15. Venous thrombosis: A multicausal disease
16. Factors V Leiden and II 20210A in patients with symptomatic pulmonary embolism and deep vein thrombosis
17. Incidence of venous thromboembolism in families with inherited thrombophilia
18. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation
19. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both
20. Gene-gene and gene-environment interactions determine risk of thrombosis in families with inherited antithrombin deficiency
21. American College of Medical Genetics consensus statement on factor V Leiden mutation testing
22. Factor V Leiden and hormone replacement therapy
23. Risks of cancer in BRCA1-mutation carriers
24. Frequency and carrier risk associated with common BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer patients
25. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews
26. Population-based study of risk of breast cancer in carriers of BRCA2 mutation
27. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study
28. BRCA1 and BRCA2: A small part of the puzzle
29. Increased frequency of genetic thrombophilia in women with complications of pregnancy
30. Surveillance improves survival of colorectal cancer in patients with hereditary nonpolyposis colorectal cancer
31. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer
32. Genetic information and health insurance: State legislative approaches
33. Discrimination as a consequence of genetic testing
34. Genetic discrimination: Perspectives of consumers
35. Genetic discrimination in life insurance: Empirical evidence from a cross sectional survey of genetic support groups in the United Kingdom
36. Genetic risk and behavioural change
37. Challenges in communicating genetics: A public health approach